Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MaxCyte, Inc. - Common Stock (NQ:MXCT)

1.610 -0.160 (-9.04%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 434,168
Open 1.760
Bid (Size) 1.520 (1)
Ask (Size) 1.620 (4)
Prev. Close 1.770
Today's Range 1.600 - 1.790
52wk Range 1.260 - 5.200
Shares Outstanding 105,482,558
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors
MaxCyte’s Flow Electroporation® Technology will support efficient gene delivery to advance Moonlight Bio’s engineered T cell therapies 
From MaxCyte, Inc
Via GlobeNewswire

Performance

YTD
-61.2%
-61.2%
1 Month
-0.6%
-0.6%
3 Month
-23.3%
-23.3%
6 Month
-37.4%
-37.4%
1 Year
-57.3%
-57.3%

More News

Read More
MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability
From MaxCyte, Inc
Via GlobeNewswire
Earnings Scheduled For August 6, 2025
Via Benzinga
Earnings Scheduled For May 7, 2025
Via Benzinga
This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
Via Benzinga
Thursday's session: top gainers and losers
Via Chartmill
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Which stocks are moving on Thursday?
Via Chartmill
A Look at MaxCyte's Upcoming Earnings Report
Via Benzinga
Traders are paying attention to the gapping stocks in Thursday's session.
Via Chartmill
MaxCyte (MXCT) Q2 Revenue Drops 18%
Via The Motley Fool
MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Signs Platform License Agreement with Adicet Bio
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025
From MaxCyte, Inc
Via GlobeNewswire
Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
These stocks are moving in today's after hours session
Via Chartmill
MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance
From MaxCyte, Inc
Via GlobeNewswire
Earnings Scheduled For March 11, 2025
Via Benzinga
MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs
From MaxCyte, Inc
Via GlobeNewswire

Frequently Asked Questions

Is MaxCyte, Inc. - Common Stock publicly traded?
Yes, MaxCyte, Inc. - Common Stock is publicly traded.
What exchange does MaxCyte, Inc. - Common Stock trade on?
MaxCyte, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for MaxCyte, Inc. - Common Stock?
The ticker symbol for MaxCyte, Inc. - Common Stock is MXCT on the Nasdaq Stock Market
What is the current price of MaxCyte, Inc. - Common Stock?
The current price of MaxCyte, Inc. - Common Stock is 1.610
When was MaxCyte, Inc. - Common Stock last traded?
The last trade of MaxCyte, Inc. - Common Stock was at 10/17/25 04:00 PM ET
What is the market capitalization of MaxCyte, Inc. - Common Stock?
The market capitalization of MaxCyte, Inc. - Common Stock is 169.83M
How many shares of MaxCyte, Inc. - Common Stock are outstanding?
MaxCyte, Inc. - Common Stock has 170M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.